Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 3Neoplasm Metastasis 3Glioblastoma 3Central Nervous System Neoplasms 3Sarcoma 2Rectal Neoplasms 2Melanoma 2Gliosarcoma 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2von Hippel-Lindau Disease 1Uterine Cervical Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Somatostatinoma 1Solitary Fibrous Tumor, Pleural 1Prostatic Neoplasms 1Primary Myelofibrosis 1Pheochromocytoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Neuroendocrine Tumors 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1

Interventions

vatalanib 1Vorinostat 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hemangioblastoma × vatalanib × Clear all
NCT00052013 2017-03-06

Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584

Novartis

Phase 2 Completed
11 enrolled

von Hippel-Lindau Disease, Hemangioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡